CAR-T Archives | Page 2 of 7

Eli Lilly Commits Up to $2.4B to Orna Therapeutics in Major Bet on In Vivo CAR-T

February 10, 2026 By BioInformant Team Leave a Comment

In news announced yesterday (February 9, 2026), Eli Lilly revealed plans to acquire Orna Therapeutics for up to $2.4 billion, a truly staggering price tag. The move marks a decisive step toward the next generation of cell therapy: programming immune cells directly inside the patient rather than manufacturing them outside the body.

Importantly, this transaction is not centered on a single pipeline candidate, but on securing a platform technology that could reshape how CAR-T and other immune-reset strategies are developed and delivered across autoimmune disease and beyond. [Read more…]

CAR-T Cell Companies Proliferate: List of CAR-T Companies Worldwide

January 17, 2026 By Cade Hildreth, Founder & President 17 Comments

CAR-T cell therapy is a type of immunotherapy that teaches T cells to recognize and destroy cancer. This article provides a comprehensive list of CAR-T therapy companies worldwide. Read on to learn more about innovative CAR-T cell therapy companies and the technologies they are using to fight cancer.

In this article:

1. Leaders of the CAR-T Industry
2. List of CAR-T Companies

[Read more…]

Vector BioMed Expands LENTIVERSE™ Platform and Unveils New Brand Identity to Close the Gap Between CGT Innovation and Patient Access

November 14, 2025 By BioInformant Team Leave a Comment

The expansion of LENTIVERSE™ platform introduces “One Lentiviral Vector Platform, Two Paths to Advance Cures,” aligning scientific rigor with transparent economics and global accessibility.

GAITHERSBURG, Md., Nov. 6, 2025 — Vector BioMed, a leading lentiviral vector supplier and contract vector development and manufacturing organization (CVDMO), today announced the expansion of its LENTIVERSE™ platform alongside the unveiling of its new brand identity, designed to accelerate global gene therapy access by providing custom and ready-to-deploy solutions. This expansion strengthens the company’s mission to make gene therapies more accessible and cost-effective for patients worldwide. [Read more…]

What is CAR-T Cell Therapy? A New Way to Treat Cancer

November 3, 2025 By Cade Hildreth, Founder & President 1 Comment

CAR-T cell therapy is as a type of immunotherapy that teaches T cells to recognize and destroy cancer. CAR-T cell therapy has demonstrated promising results in a range of patients across the globe. In some patients, this can lead to the total elimination of the cancer. In others, there is a significant improvement of the disease.

For those confronting cancer, one crucial question often arises: What is CAR-T cell therapy? This guide answers the most common questions and explains how this innovative technology is transforming the future of cancer treatment.

[Read more…]

Celularity – Big Bucks, Billionaire Investors, Bold Dreams

June 18, 2023 By Cade Hildreth, Founder & President Leave a Comment

Celularity is a biotechnology company that specializes in leveraging biologically active cell populations within the postpartum human placenta. Founded on the pioneering work of Robert Hariri, MD, PhD, in human placenta-derived cellular therapeutics and biomaterials, Celularity is uniquely positioned to harness the potential of most biocreative event on earth: human birth. [Read more…]